SCHEMBL1150488

SCHEMBL1150488

Cc1ccc(F)cc1.O=S(=O)(Cl)Cl

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.68
NFE2L2 Q16236 1/20 0.52
BCHE P06276 1/20 0.48
GAA P10253 2/20 0.46
KMT2A Q03164 4/20 0.44
MEN1 O00255 2/20 0.44
PAX8 Q06710 1/20 0.44
TP53 P04637 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
EGFR P00533 1/20 0.43
ERBB2 P04626 1/20 0.43
FFAR4 Q5NUL3 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA3 P07451 1/20 0.42
CA6 P23280 1/20 0.42
CA5A P35218 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27713190 0.89 GAA (0.67) ACHEBCHEGAAKMT2AMEN1
SCHEMBL1603078 0.86 CA1 (0.46) ACHEKMT2AMEN1CA1CA2
P-Xylene SCHEMBL4025615 0.86 GAA (0.58) ACHEGAACA12CA1CA2
SCHEMBL7025938 0.83
SCHEMBL12689 0.83
Formaldehyde SCHEMBL27896135 0.80 ACHE (0.81) ACHENFE2L2BCHEGAAKMT2A
SCHEMBL14509444 0.80 ACHE (0.62) ACHENFE2L2BCHEGAAKMT2A
SCHEMBL4792586 0.80 GAA (0.76) ACHEBCHEGAAKMT2AMEN1
Fluoride SCHEMBL28844251 0.80
Ammonia Solution, Strong SCHEMBL359474 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3426246-B1 THIAZOLIDINONE COMPOUNDS AND USE THEREOF NATIONAL HEALTH RES INST (TW) 2024-05-01 EP disclosed
US-20230331719-A1 Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same OPTIKIRA LLC (US) 2023-10-19 US disclosed
EP-4192462-A1 PYRAZOLOPYRIDINE COMPOUNDS AND METHODS OF INHIBITING IRE1 USING SAME Optikira LLC (US) 2023-06-14 EP disclosed
WO-2022032078-A1 PYRAZOLOPYRIDINE COMPOUNDS AND METHODS OF INHIBITING IRE1 USING SAME Optikira, LLC (US) 2022-02-10 WO disclosed
US-10544113-B2 Thiazolidinone compounds and use thereof NATIONAL HEALTH RESEARCH INSTITUTE (TW) 2020-01-28 US disclosed
EP-3426246-A1 THIAZOLIDINONE COMPOUNDS AND USE THEREOF National Health Research Institutes (TW) 2019-01-16 EP disclosed
WO-2017155910-A1 THIAZOLIDINONE COMPOUNDS AND USE THEREOF NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2017-09-14 WO disclosed
US-20170253569-A1 THIAZOLIDINONE COMPOUNDS AND USE THEREOF REGENTS OF THE UNIVERSITY OF MINNESOTA 2017-09-07 US disclosed
CN-103958521-B Pyrimidin-4-one derivatives and their use in the treatment, alleviation or prevention of viral diseases 弗·哈夫曼-拉罗切有限公司 2016-10-19 CN disclosed
CN-103958475-B Heteroaryl hydroxamic acid derivatives and their use in the treatment, alleviation or prevention of viral diseases F. HOFFMANN-LA ROCHE AG (CH) 2015-11-25 CN disclosed
CN-1751044-A Sulfonamide substituted xanthine derivatives for use as PEPCK inhibitors HOFFMANN LA ROCHE (CH) 2006-03-22 CN disclosed
US-20050240001-A1 2-(2-Amino-2-methylpropionylamino)-3-(2,6-difluoro-3-methylphenyl)methoxy propionic acid N-[5-(4-chlorophenyl)-3,3-dimethyl-1,1-dioxo-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide; endogenous human growth hormone controller; non-peptidyl in nature, more metabolically stable ELI LILLY AND COMPANY (US) 2005-10-27 US disclosed
CN-1639158-A Thiazole derivatives as NPY receptor antagonists HOFFMANN LA ROCHE (CH) 2005-07-13 CN disclosed
EP-1497316-A2 GROWTH HORMONE SECRETAGOGUES ELI LILLY AND COMPANY (US) 2005-01-19 EP disclosed
US-20040063669-A1 Alpha-phenyl-beta-ketosulfone FISCHER REINER (DE) 2004-04-01 US disclosed
US-6670385-B1 Fungicides, herbicides and insecticides for crops BAYER AKTIENGESELLSCHAFT (DE) 2003-12-30 US disclosed
WO-2003087070-A2 GROWTH HORMONE SECRETAGOGUES ELI LILLY AND COMPANY (US) 2003-10-23 WO disclosed
WO-1997046207-A2 AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS CORVAS INTERNATIONAL, INC. (US) 1997-12-11 WO disclosed
EP-0804464-A1 AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS CORVAS INTERNATIONAL, INC. (US) 1997-11-05 EP disclosed
WO-1996018644-A1 AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS CORVAS INTERNATIONAL, INC. (US) 1996-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10544113-B2 Thiazolidinone compounds and use thereof OPRL1, OPRD1, OPRK1 ACHE 829/4885NFE2L2 1730/4885BCHE 2434/4885
US-20040063669-A1 Alpha-phenyl-beta-ketosulfone CYP2S1, SULT1E1, SKP1 ACHE 2243/4885NFE2L2 805/4885BCHE 2320/4885
US-20230331719-A1 Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same XBP1, ERN1, ERN2 ACHE 1380/4885NFE2L2 400/4885BCHE 2991/4885
US-20170253569-A1 THIAZOLIDINONE COMPOUNDS AND USE THEREOF OPRL1, OPRD1, OPRK1 ACHE 829/4885NFE2L2 1730/4885BCHE 2434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.